Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Sign In
Free Trial
Sign In
Free Trial
Search
Search
Pink Sheet
Pink Sheet Perspectives
Regulatory Trackers
US FDA Performance Tracker
User Fee Goal Dates
CDER Novel Approvals
CBER Novel Approvals
Breakthrough Designations
RMAT Designations
QIDP Designations
Biosimilars
Complete Response Letters
Advisory Committees
European Performance Tracker
EU Filings
EU CHMP Opinions & MAA Updates
EU Approvals
EU Accelerated Assessment Tracker
EU Biosimilar Filings, Opinions & Approvals
EMA PRIME Scheme
Global Pharma Guidance Update
Global Pharma Guidance Tracker
Regional Comparisons
Interviews
Pathways & Standards
Approval Standards
Review Pathways
User Fees
Product Reviews
US Advisory Committees
EU CHMP
Approvals
Complete Response Letters
Drug Review Profiles
Post-Marketing Regulation & Studies
Agency Leadership
EMA
US FDA
Drug Safety
Market Access
Health Technology Assessment
Pricing Debate
PBMs
Government Payers
Medicaid
Medicare
Legislation
Elections
EU Pharma Legislation Reform
Legal & IP
Patents
Litigation
Compliance
Marketing & Advertising
Manufacturing
Distribution/Supply Chain
R&D
Clinical Trials
Diversity & Inclusion
Real-World Evidence
Rare Diseases
Vaccines
Advanced Technologies
AI
Digital Technologies
Cell & Gene Therapies
Platform Technologies
Biosimilars & Generics
Biosimilars
Generics
Conferences
DIA
BIO
Geography
Asia
China
India
Japan
South Korea
Europe
United Kingdom
France
Germany
Italy
Spain
Latin America
Middle East & Africa
North America
United States
Canada
International
Podcasts
Partnered Content
Isis Hits LDL Milestone In Bristol-Myers Squibb Deal
09 Apr 2008
•
By
Emily Hayes
Firm talent-spots PCSK9 compound to the tune of $2 million.
More from Archive
More from Pink Sheet
search by queryly
Advanced Search
